Harvard Bioscience (HBIO) Cash from Operations (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Cash from Operations data on file, last reported at 662000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 662000.0, down 122.17% year-over-year; the trailing twelve-month figure through Mar 2026 was 3081000.0 (up 1.92% YoY), and the FY2025 annual result was 6729000.0, up 367.29% from the prior year.
• Cash from Operations retreated to 662000.0 in Q1 2026 per HBIO's latest filing, from 96000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 4361000.0 in Q3 2023 and troughed at 1986000.0 in Q1 2022.
• A 5-year average of 1334529.41 and a median of 1403000.0 in 2024 frame the typical range for Cash from Operations.
• On a YoY basis, Cash from Operations climbed as much as 2189.74% in 2022 and fell as far as 291.51% in 2022.
• A 5-year view of Cash from Operations shows it stood at 2679000.0 in 2022, then jumped by 60.62% to 4303000.0 in 2023, then sank by 59.91% to 1725000.0 in 2024, then sank by 105.57% to 96000.0 in 2025, then tumbled by 589.58% to 662000.0 in 2026.
• Business Quant data shows HBIO's Cash from Operations at 662000.0 in Q1 2026, 96000.0 in Q4 2025, and 1084000.0 in Q3 2025.